Switch to infliximab biosimilar safe and effective in IBD: study
An Australian prospective study demonstrates outcomes are non-inferior to those with the originator biologic, researchers say
Patients with IBD in remission who switch from infliximab to a biosimilar, CT-P13, have non-inferior clinical outcomes to those who remain on the originator, Australian data show.
The Switching Australian patients with Moderate to Severe inflammatory bowel diseasE (SAME) study included 345 adults (232 with Crohn’s disease) being treated with infliximab who had been in stable clinical or biochemical remission, free of steroids, for at least 12 weeks.
They were allocated either to remain on infliximab
